Skip to content

Ayurvedic management in Rheumatoid Arthritis

A clinical study on the efficacy of sunthi arka in the management of amavata (rheumatoid arthritis) - NIL

Status
Active, not recruiting
Phases
Phase 4
Study type
Interventional
Source
CTRI
Registry ID
CTRI/2026/04/107326
Enrollment
30
Registered
2026-04-01
Start date
Unknown
Completion date
Unknown
Last updated
2026-04-27

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: M057- Rheumatoid arthritis with rheumatoid factor without organ or systems involvement

Interventions

None listed

Sponsors

Government of West Bengal
Lead Sponsor

Eligibility

Inclusion criteria

Inclusion criteria: 1. Patients diagnosed with Amavata as per classical Ayurvedic signs and symptoms and meeting the diagnostic criteria for Rheumatoid Arthritis (RA) as per ACR/EULAR 2010. 2. Age group: 18-70 years.Either gender. 3. Patients with disease duration greater than equal to 5 years. 4. Both seropositive and seronegative RA patients (RA factor(positive or negetive)), Anti-CCP (positive or Negetive)). 5. Patients willing to participate and provide informed written consent. 6. Patients with mild to moderate disease activity (DAS28 score greater than equal to 5.1). 6. Patients who can follow study instructions and visit regularly for follow-up.

Exclusion criteria

Exclusion criteria: 1.Patients below 18 years and above 70 years 2. Advanced deformities of joints. 3. Patients with other autoimmune diseases (e.g., SLE, psoriasis). 4.Pregnant/lactating women. 5. Severe systemic disorders (renal failure, uncontrolled diabetes, uncontrolled hypertension etc.). 6. Patients on steroids or immunosuppressant. 7. Any cardiac disease 8. Patients with active tuberculosis or known malignancy. 9. Drug or alcohol abuse interfering with compliance.

Design outcomes

Primary

MeasureTime frame
Reduction in pain, stiffness and swelling based on clinical scoring.(DAS 28 score - (with ESR/CRP)) Timepoint: At Baseline, after Treatment on 1st week, 2nd week and 4th week.

Secondary

MeasureTime frame
1. Improvement in ESR and RA factor levels. 2. The patient reported improvement in mobility and daily activityTimepoint: At Baseline, after Treatment on 1st week, 2nd week and 4th week.

Countries

India

Contacts

Public ContactDr.Anupam Nayak

The West Bengal University of Health Sciences

drdebabrataghosh29@gamil.com9064184769

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: May 1, 2026